Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo‐controlled, dose‐finding trial followed by 24 months of treatment
出版年份 2022 全文链接
标题
Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo‐controlled, dose‐finding trial followed by 24 months of treatment
作者
关键词
-
出版物
EUROPEAN JOURNAL OF NEUROLOGY
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2022-07-15
DOI
10.1111/ene.15499
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Understanding European patient expectations towards current therapeutic development in spinal muscular atrophy
- (2021) Nicole Gusset et al. NEUROMUSCULAR DISORDERS
- Risdiplam in Type 1 Spinal Muscular Atrophy
- (2021) Giovanni Baranello et al. NEW ENGLAND JOURNAL OF MEDICINE
- Understanding the relationship between the 32-item motor function measure and daily activities from an individual with spinal muscular atrophy and their caregivers’ perspective: a two-part study
- (2021) Tina Duong et al. BMC Neurology
- Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls
- (2021) Basil T. Darras et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial
- (2021) Eugenio Mercuri et al. LANCET NEUROLOGY
- Long-term follow-up of patients with type 2 and non-ambulant type 3 spinal muscular atrophy (SMA) treated with olesoxime in the OLEOS trial
- (2020) Francesco Muntoni et al. NEUROMUSCULAR DISORDERS
- Natural history of Type 2 and 3 spinal muscular atrophy: 2‐year NatHis‐SMA study
- (2020) Mélanie Annoussamy et al. Annals of Clinical and Translational Neurology
- Revised upper limb module for spinal muscular atrophy: 12 month changes
- (2019) Maria Carmela Pera et al. MUSCLE & NERVE
- Long-term progression in type II spinal muscular atrophy
- (2019) Eugenio Mercuri et al. NEUROLOGY
- Clinical Evidence Supporting Early Treatment Of Patients With Spinal Muscular Atrophy: Current Perspectives
- (2019) Tamara Dangouloff et al. Therapeutics and Clinical Risk Management
- Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
- (2018) Eugenio Mercuri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 (SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA)
- (2018) Hasane Ratni et al. JOURNAL OF MEDICINAL CHEMISTRY
- Prospective and longitudinal natural history study of patients with Type 2 and 3 spinal muscular atrophy: Baseline data NatHis-SMA study
- (2018) Aurélie Chabanon et al. PLoS One
- A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier
- (2018) Stefan Sturm et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial
- (2017) Enrico Bertini et al. LANCET NEUROLOGY
- Specific Correction of Alternative Survival Motor Neuron 2 Splicing by Small Molecules: Discovery of a Potential Novel Medicine To Treat Spinal Muscular Atrophy
- (2016) Hasane Ratni et al. JOURNAL OF MEDICINAL CHEMISTRY
- Severe impairment of male reproductive organ development in a low SMN expressing mouse model of spinal muscular atrophy
- (2016) Eric W. Ottesen et al. Scientific Reports
- Childhood spinal muscular atrophy: controversies and challenges
- (2012) Eugenio Mercuri et al. LANCET NEUROLOGY
- Prospective cohort study of spinal muscular atrophy types 2 and 3
- (2012) P. Kaufmann et al. NEUROLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started